Pooled summary estimates for rifampicin resistance
| Subgroup | Pooled sensitivity | Pooled specificity | Pooled LR+ | Pooled LR- | Pooled DOR |
| All rifampicin studies# | 98.1 (95.9–99.1) | 98.7 (97.3–99.4) | 78.0 (36.3–168.0) | 0.02 (0.01–0.04) | 4010.1 (1205.9–13335.2) |
| Only MTBDRplus assays¶ | 98.4 (95.1–99.5) | 98.9 (96.8–99.7) | 95.3 (30.7–296.0) | 0.02 (0.005–0.05) | 6150.7 (1061.8–35628.9) |
| Only clinical specimens+ | 98.6 (95.5–99.6) | 98.5 (96.9–99.3) | 66.3 (31.9–138.0) | 0.01 (0.004–0.04) | 4659.3 (1064.6–20391.3) |
Data are presented as % (confidence interval). MTBDRplus is manufactured by Hain LifeScience GmbH (Nehren, Germany). LR+: positive likelihood ratio; LR-: negative likelihood ratio; DOR: diagnostic odds ratio. #: number of comparisons was 14; ¶: number of comparisons was 4; +: number of comparisons was 9.